Abstract
7063 Background: Survival of chronic myeloid leukemia (CML) has improved since FDA approval of imatinib in May 2001. However, there is limited data on survival pattern of elderly patients. We condu...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
